| Literature DB >> 35221380 |
Abstract
The purpose of the proposed review is to refer the contemporary capability of automated analytical systems, in particular batch injection analysis (BIA) in connection with electrochemical detection, for widespread applications in analytical chemistry. This combination recently represents an efficient tool for improvement of method parameters, such as speed, selectivity, and sampling rate for sensing of miscellaneous organic and inorganic substances. The review is focused on conception and usage of BIA in tandem with electrochemical detection utilizing various techniques, namely amperometry, voltammetry, and multiple pulse amperometry, as well as design of electrochemical cells constructed for BIA systems is discussed. Finally, this paper also summarizes the comprehensive overview of works published from 2015 to 2020 dealing with the electrochemical determination of different analytes by BIA in various matrices. © Springer-Verlag GmbH Austria, part of Springer Nature 2022.Entities:
Keywords: Amperometry; Automated analytical system; Batch injection analysis; Electrochemistry; Voltammetry
Year: 2022 PMID: 35221380 PMCID: PMC8863510 DOI: 10.1007/s00706-022-02898-9
Source DB: PubMed Journal: Monatsh Chem ISSN: 0026-9247 Impact factor: 1.451
Fig. 1Components of FIA system [1]: P pump, C carrier stream of liquid, R reagent, S injection port, MC mixing cell, D detector, W waste
Fig. 2Number of publications derived from WoS database issued from 2000 to 2020 regarding: 1. FIA (keywords: “flow injection analysis” electrochemical detection + category—“chemistry analytical” 923 articles, 85 review articles); 2. SIA (keywords: “sequential injection analysis” electrochemical detection + category—“chemistry analytical” 40 articles, 10 review articles); and 3. BIA (keywords: “batch injection analysis” electrochemical detection + category—“chemistry analytical” 78 articles, 7 review articles)
Fig. 3Scheme of BIA cell: A working electrode; B counter electrode; C reference electrode; D micropipette tip; E hole; F stirring bar; G drainage [6]
Fig. 4Steps in BIA operation: A before injection, B transport during the injection, C end of the injection, D washing out, E final equilibrium [27]
Fig. 5Scheme of manufacturing of 3D printing electrodes and BIA cells [31]
Fig. 6Current responses for electrochemical oxidation of 2 × 10–3 mol dm−3 K4[Fe(CN)6] in 0.4 mol dm−3 K2SO4 at a Pt electrode; injection flow rate of 24.5 mm3 s−1. a Point-by-point pseudo-steady-state voltammetric curve after consecutive injections of 16 mm3 during a potential sweep at scan rate 10 mV s−1; b cyclic voltammogram recorded after injection of 100 mm3 at scan rate 100 mV s−1; c square-wave voltammogram recorded during injection of 100 mm3 at frequency of 100 Hz and amplitude of 50 mV [36]
Overview of basic characteristics and parameters of voltammetric and amperometric determination of selected analytes using BIA (published in 2015–2020, alphabetically ordered according to analyte)
| Analyte | Supporting electrolyte | Working electrode | Detection potential/V | Technique | LOD/10–6 g dm−3 | Analyzed sample | References |
|---|---|---|---|---|---|---|---|
| α-Amylase | 0.1 mol dm−3 NaOH | CuO–CuE | + 0.60 | Amperometry | 50.0 × 10–6 *mol dm−3 | Biological (saliva) | [ |
| α-Lipoic acid | PBS pH 7.0 | CoPc–PGE | + 0.90 | Amperometry | 3.1 | Food (supplement) biological (urine) | [ |
| 2,2-Diphenyl-1-picrylhydrazyl | ABS pH 5.5 with ethanol (40/60, | GCE | + 0.05 | Amperometry | 394.3 | Environmental (plant extract) | [ |
| 2,6-Di- | 0.1 mol dm−3 HClO4 with 99% ethanol ( | SPGE | + 1.10 | Amperometry | 290.0 | Jet fuel | [ |
| 4-Chloroaniline | 0.03 mol dm−3 acetic acid | MWCNTs–GCE | + 1.00 | Amperometry | 6.4 | Pharmaceutical (skin disinfectant) | [ |
| 8-Chlorotheophylline | 0.05 mol dm−3 acetic acid with ABS; pH 4.7 | BDDE | + 1.10 | MPA | 66.5 | Pharmaceutical (tablets) | [ |
| 0.1 mol dm−3 H2SO4 | BDDE | + 1.25 | MPA | 40.8 | Pharmaceutical (oral solution) | [ | |
| Acetylcysteine | 1.0 mol dm−3 KOH | NiPb–FTOE | + 0.40 | Amperometry | 37.5 | Pharmaceutical (injectable solution) | [ |
| Acetylsalicylic acid | 0.1 mol dm−3 H2SO4 | BDDE | + 1.30 | MPA | 164.0 | Pharmaceutical (tablets) | [ |
| Amiloride | BBS pH 10.0 | BDDE | + 0.85 | MPA | 130.0 | Pharmaceutical (capsules) | [ |
| Aminophylline | PBS pH 7.0 | SPCE | + 0.90 | MPA | 12.6 | Pharmaceutical (tablets, capsules) | [ |
| Amlodipine | BRBS pH 2.0 | BDDE | + 1.00 | Amperometry | 30.3 | Pharmaceutical (tablets) | [ |
| Ampicillin | BRBS pH 7.0 | CuE | + 0.025 | Amperometry | 2500 | Pharmaceutical (tablets) | [ |
| Astaxanthin | Acetone, dichloromethane, water (80:10:10, | GCE | + 0.80 | Amperometry | 179.1 | Environmental (salmon) | [ |
| Atenolol | BRBS pH 2.0 | BDDE | + 1.65 | Amperometry | 19.4 | Pharmaceutical (tablets) | [ |
| Benzocaine | PBS pH 7.0 | SPCE | + 0.90 | Amperometry | 5.0 | Environmental (fish fillets) | [ |
| Caffeine | 0.05 mol dm−3 acetic acid with ABS; pH 4.7 | BDDE | + 1.40 | MPA | 95.2 | Pharmaceutical (tablets) | [ |
| 0.1 mol dm−3 H2SO4 | BDDE | + 1.60 | MPA | 79.6 | Pharmaceutical (tablets) | [ | |
| 0.1 mol dm−3 H2SO4 | BDDE | + 1.55 | SWV | 291.3 | Pharmaceutical (tablets) | [ | |
| 0.1 mol dm−3 H2SO4 | BDDE | + 1.60 | MPA | 100 | Pharmaceutical (tablets) | [ | |
| PBS pH 6.86 | IrOx/RuOx–GCE | + 1.25 | Amperometry | – | Pharmaceutical (tablets) | [ | |
| Captopril | ABS pH 4.7 | BDDE | + 1.40 | MPA | 30.4 | Pharmaceutical (tablets) | [ |
| Carbamazepine | PBS pH 7.0 | SPCE | + 1.00 | MPA | 99.2 | Pharmaceutical (tablets, capsules) | [ |
| Carbendazim | BRBS pH 4.0 | MWCNTs–SPE | + 0.80 | MPA | 11.5 | Environmental (tap water) | [ |
| Catechin | ABS pH 4.5 | SPCE | + 0.30 | Amperometry | 6.1 | Environmental (plant extract) | [ |
| ABS pH 4.5 | GCE | + 0.40 | MPA | 8.7 | Food (green tea) | [ | |
| Catechol | 0.1 mol dm−3 HClO4 | NF–MWCNTs–GCE | + 0.60 | Amperometry | 6.6 | – | [ |
| 0.1 mol dm−3 HClO4 | GCE | + 0.60 | Amperometry | 68.9 | – | [ | |
| 0.1 mol dm−3 HClO4 | ErGO–GCE | + 0.60 | Amperometry | 3.4 | – | [ | |
| 0.1 mol dm−3 HClO4 | CrGO–GCE | + 0.60 | Amperometry | 1.3 | – | [ | |
| 0.1 mol dm−3 HClO4 | BDDE | + 0.80 | Amperometry | 13.7 | Clinical (serum) | [ | |
| 0.1 mol dm−3 HClO4 | rGO–BDDE | + 0.80 | Amperometry | 6.2 | Clinical (serum) | [ | |
| 0.1 mol dm−3 HClO4 | MWCNTs–BDDE | + 0.80 | Amperometry | 2.3 | Clinical (serum) | [ | |
| 0.1 mol dm−3 HClO4 | MWCNTs/rGO–BDDE | + 0.80 | Amperometry | 1.3 | Clinical (serum) | [ | |
| BRBS pH 4.0 | MWCNTs–SPE | + 0.50 | MPA | 5.5 | Environmental (tap water) | [ | |
| Chlorine monoxide | BRBS pH 6.0 with 0.05 mol dm−3 KCl | ITOE | 0.00 | Amperometry | 108.1 | Environmental (tap water) | [ |
| Chlorpheniramine | BRBS pH 10.0 | BDDE | + 1.10 | MPA | 137.4 | Pharmaceutical (tablets) | [ |
| Ciprofloxacin | BRBS pH 4.0 | NF–MWCNTs–GCE | + 1.20 | Amperometry | 13.3 | – | [ |
| BRBS pH 4.0 | MWCNTs–SPE | + 1.00 | Amperometry | 19.9 | Pharmaceutical (tablets, injectable solution) | [ | |
| Clindamycin | PBS pH 7.0 | SPCE | + 0.80 | MPA | 21.3 | Pharmaceutical (tablets, capsules) | [ |
| Cocaine | 0.1 mol dm−3 HClO4 | BDDE | + 2.10 | SWV | 270.0 | Seized sample | [ |
| Colchicine | PBS pH 7.0 | SPCE | + 1.10 | MPA | 39.9 | Pharmaceutical (tablets, capsules) | [ |
| Cu | 0.1 mol dm−3 HCl | SPAuE | + 0.20 | SWASV | 0.5 | Biodiesel | [ |
| Diphenhydramine | 0.05 mol dm−3 acetic acid with ABS; pH 4.7 | BDDE | + 1.70 | MPA | 194.1 | Pharmaceutical (tablets) | [ |
| 0.1 mol dm−3 H2SO4 | BDDE | + 1.80 | MPA | 46.0 | Pharmaceutical (oral solution) | [ | |
| Dopamine | 0.1 mol dm−3 HClO4 | NF–MWCNTs–GCE | + 0.70 | Amperometry | 6.1 | – | [ |
| 0.1 mol dm−3 HClO4 | GCE | + 0.60 | Amperometry | 50.7 | – | [ | |
| 0.1 mol dm−3 HClO4 | ErGO–GCE | + 0.60 | Amperometry | 5.0 | – | [ | |
| 0.1 mol dm−3 HClO4 | CrGO–GCE | + 0.60 | Amperometry | 8.4 | – | [ | |
| 0.1 mol dm−3 HClO4 | BDDE | + 0.80 | Amperometry | 15.6 | Clinical (serum) | [ | |
| 0.1 mol dm−3 HClO4 | rGO–BDDE | + 0.80 | Amperometry | 13.2 | Clinical (serum) | [ | |
| 0.1 mol dm−3 HClO4 | MWCNTs–BDDE | + 0.80 | Amperometry | 12.1 | Clinical (serum) | [ | |
| 0.1 mol dm−3 HClO4 | MWCNTs/rGO–BDDE | + 0.80 | Amperometry | 2.5 | Clinical (serum) | [ | |
| PBS pH 7.0 | GPE | + 0.30 | Amperometry | 55.1 | – | [ | |
| PBS pH 7.0 | EGPE | + 0.30 | Amperometry | 41.4 | – | [ | |
| PBS pH 7.0 | O2GPE | + 0.30 | Amperometry | 44.4 | – | [ | |
| PBS pH 7.0 | CO2GPE | + 0.30 | Amperometry | 29.1 | – | [ | |
| 0.1 mol dm−3 KCl | SnHCF–BDDE | + 0.90 | Amperometry | 32.2 | Biological (saliva) | [ | |
| 0.1 mol dm−3 HClO4 | ZnO/MWCNTs–GCE | + 0.60 | Amperometry | 21.5 | – | [ | |
| Epinephrine | PBS pH 7.0 | SSE | + 0.50 | Amperometry | 183.2 | Pharmaceutical (injectable solution) | [ |
| Fipronil | 0.1 mol dm−3 HClO4/acetone (50:50, | GCE | + 1.60 | Amperometry | 2100 | Environmental (insecticide) | [ |
| 0.1 mol dm−3 HClO4/acetone (50:50, | MWCNTs–GCE | + 1.60 | Amperometry | 1100 | Environmental (insecticide) | [ | |
| Folic acid | 0.1 mol dm−3 NaOH | [(NiIITRPyP)-μ-O2]n–GCE | + 0.50 | Amperometry | 325.3 | Pharmaceutical (tablets) | [ |
| Furosemide | BBS pH 10.0 | BDDE | + 1.20 | MPA | 940.0 | Pharmaceutical (capsules) | [ |
| BRBS pH 4.0 | BDDE | + 1.30 | MPA | 215.0 | Pharmaceutical (tablets) biological (urine) | [ | |
| ABS pH 5.2 | CrGO–GCE | + 1.00 | amperometry | 231.5 | Environmental (natural water) | [ | |
| Gentamicin sulfate | ABS pH 4.4 | BDDE | + 2.00 | Amperometry | 339.1 | Pharmaceutical (injectable solution) | [ |
| Glucose/H2O2 | PBS with 0.1 mol dm−3 KCl pH = 6.0 | CE | − 0.25 | Amperometry | 19,800 | Clinical (artificial serum) | [ |
| H2O2 | BRBS pH 4.0 | ITOE | − 0.05 | Amperometry | 295.9 | Environmental (tap water) | [ |
| Hg | 0.1 mol dm−3 HCl | SPAuE | + 0.40 | SWASV | 0.7 | Biodiesel | [ |
| Hydralazine | 1 mol dm−3 KOH | NiPt–FTOE | + 0.45 | Amperometry | 949.8 | Pharmaceutical (tablets) | [ |
| Hydrochlorothiazide | ABS pH 4.7 | BDDE | + 1.80 | MPA | 80.4 | Pharmaceutical (tablets) | [ |
| BRBS pH 4.0 | BDDE | + 1.10 | MPA | 187.6 | Pharmaceutical (tablets) biological (urine) | [ | |
| Hydroquinone | 0.1 mol dm−3 HClO4 | NF–MWCNTs–GCE | + 0.70 | Amperometry | 5.5 | – | [ |
| 0.1 mol dm−3 HClO4 | GCE | + 0.50 | Amperometry | 17.4 | – | [ | |
| 0.1 mol dm−3 HClO4 | ErGO–GCE | + 0.50 | Amperometry | 6.3 | – | [ | |
| 0.1 mol dm−3 HClO4 | CrGO–GCE | + 0.50 | Amperometry | 5.7 | – | [ | |
| BRBS pH 4.0 | MWCNTs–SPE | + 0.30 | MPA | 2.2 | Environmental (tap water) | [ | |
| 0.1 mol dm−3 HClO4 | ZnO/MWCNTs–GCE | + 0.60 | Amperometry | 1.1 | – | [ | |
| Levamisole | BRBS pH 8.0 | SPCE | + 1.20 | Amperometry | 28.6 | Pharmaceutical (tablets) | [ |
| Levofloxacin | BRBS pH 5.0 | BDDE | + 1.30 | Amperometry | 36.1 | Environmental (tap water, lake water) | [ |
| Minoxidil | PBS pH 7.0 | SPCE | + 0.90 | MPA | 29.3 | Pharmaceutical (tablets, capsules) | [ |
| Naphazoline | BRBS pH 10.0 | BDDE | + 1.30 | MPA | 21.0 | Pharmaceutical (tablets) | [ |
| ABS pH 4.7 | BDDE | + 1.45 | SWASV | 8.4 | Pharmaceutical (solution) | [ | |
| NO2– | BRBS pH 2.0 | MWCNTs–SPCE | + 0.70 | MPA | 2.8 | Biological (urine, saliva) clinical (serum, plasma) | [ |
| Omeprazole | BRBS pH 6.0 | NF–MWCNTs–GCE | + 1.00 | Amperometry | 3.5 | – | [ |
| BRBS pH 8.0 | MWCNTs–SPCE | + 1.10 | Amperometry | 3.1 | Pharmaceutical (tablets) | [ | |
| Paracetamol | 0.1 mol dm−3 H2SO4 | BDDE | + 1.00 | MPA | 240.4 | Pharmaceutical (tablets) | [ |
| 0.1 mol dm−3 H2SO4 | BDDE | + 0.80 | SWV | 302.3 | pharmaceutical (tablets) | [ | |
| 0.1 mol dm−3 H2SO4 | BDDE | + 0.90 | MPA | 200 | Pharmaceutical (tablets) | [ | |
| Pb | 0.1 mol dm−3 HCl | SPAuE | − 0.22 | SWASV | 1.0 | Biodiesel | [ |
| Phenazopyridine | PBS pH 7.0 with methanol (70:30, | BDDE | + 0.75 | MPA | 50.0 | Pharmaceutical (tablets) | [ |
| Pheniramine | BRBS pH 10.0 | BDDE | + 1.10 | MPA | 144.2 | Pharmaceutical (eye drop) | [ |
| Picoxystrobin | BRBS pH 2.0 | BDDE | + 1.90 | Amperometry | 587.7 | Food (mineral water, spiked) | [ |
| Prazosin | PBS pH 7.0 | SPCE | + 0.70 | MPA | 19.2 | Pharmaceutical (tablets, capsules) | [ |
| Procainamide | PBS pH 7.0 | SPCE | + 0.90 | MPA | 6.5 | Pharmaceutical (tablets, capsules) | [ |
| Propyphenazone | 0.1 mol dm−3 H2SO4 | BDDE | + 1.30 | SWV | 200.4 | Pharmaceutical (tablets) | [ |
| 0.1 mol dm−3 H2SO4 | BDDE | + 1.20 | MPA | 300 | Pharmaceutical (tablets) | [ | |
| Pyridoxine | 0.1 mol dm−3 H2SO4 | BDDE | + 1.60 | MPA | 91.4 | Pharmaceutical (oral solution) | [ |
| Pyrogallol | 0.1 mol dm−3 HClO4 | MWCNT–GCE | + 0.90 | Amperometry | 1.6 | Biodiesel | [ |
| Quercetin | PBS pH 6.0 with ethanol (80:20, | GCE | + 0.30 | MPA | 1.2 | Environmental (plant extract) | [ |
| PBS pH 6.0 with ethanol (80:20, | SPCE | + 0.20 | Amperometry | 8.2 | Environmental (plant extract) | [ | |
| Ranitidine | 0.1 mol dm−3 NaCl | rGO/RuOHCF–GCE | + 1.10 | Amperometry | 86.2 | Pharmaceutical (tablets) | [ |
| Scopolamine | 0.5 mol dm−3 H2SO4 | BDDE | + 1.80 | SWV | 54.6 | Food (beverage) | [ |
| Sibutramine | 0.1 mol dm−3 H2SO4 | BDDE | + 1.80 | SWV | 80.0 | Environmental (herbals) food (dietary) supplements) | [ |
| Sildenafil | BRBS pH 2.0 | SPCE | + 1.10 | Amperometry | 24.7 | Pharmaceutical (tablets) | [ |
| Levothyroxine sodium | 0.05 mol dm−3 H2SO4 (80% methanol) | G–ORSPE | + 0.80 | Amperometry | 80.0 | Pharmaceutical (tablets) | [ |
| Sulfamethoxazole | PBS pH 7.0 | BDDE | + 1.20 | MPA | 227.0 | Pharmaceutical (tablets) | [ |
| PBS pH 7.0 with methanol (70:30, | BDDE | + 1.00 | MPA | 150.0 | Pharmaceutical (tablets) | [ | |
| Tadalafil | BRBS pH 4.0 with 5% DMSO | BDDE | + 1.30 | Amperometry | 389.4 | Pharmaceutical (tablets) | [ |
| 0.1 mol dm−3 HClO4 | NF–MWCNT–GCE | + 0.50 | Amperometry | 86.4 | – | [ | |
| 0.1 mol dm−3 HClO4 | ZnO/MWCNT–GCE | + 0.60 | Amperometry | 13.3 | – | [ | |
| Tetracycline | BRBS pH 10.0 | CrGO–GCE | + 0.90 | Amperometry | 16.9 | Pharmaceutical (tablets) food (milk) | [ |
| Theophylline | PBS pH 7.0 | SPCE | + 0.90 | MPA | 5.4 | Pharmaceutical (tablets, capsules) | [ |
| Tricaine | PBS pH 7.0 | SPCE | + 0.75 | Amperometry | 8.3 | Environmental (fish fillets) | [ |
| Trimethoprim | PBS pH 7.0 | BDDE | + 1.00 | MPA | 173.0 | Pharmaceutical (tablets) | [ |
| Trimethoprim | PBS pH 7.0 with methanol (70:30, | BDDE | + 1.30 | MPA | 200.0 | Pharmaceutical (tablets) | [ |
| Uric acid | BRBS pH 2.0 | MWCNTs–SPCE | + 0.45 | MPA | 8.4 | Biological (urine, saliva) clinical (serum, plasma) | [ |
| 2 mol dm−3 KOH | NiZn–FTOE | + 0.10 | Amperometry | 3.9 | Biological (urine, saliva) | [ | |
| Verapamil | PBS pH 7.0 | SPCE | + 1.00 | MPA | 9.1 | Pharmaceutical (tablets, capsules) | [ |
| Warfarin | PBS pH 7.0 | SPCE | + 1.00 | MPA | 21.6 | Pharmaceutical (tablets, capsules) | [ |
| PBS pH 7.0 | BDDE | + 1.20 | MPA | 111.0 | Pharmaceutical (tablets) | [ | |
| Zn | ABS pH 4.7 | BDDE | – 1.00 | SWASV | 8.2 | Pharmaceutical (solution) | [ |
| BRBS pH 7.0 | AuE | – 0.55 | ASV | 5.0 | Bioethanol | [ |
Supporting electrolyte: ABS acetate buffer solution, BBS borate-buffered saline, BRBS Britton-Robinson buffer solution, PBS phosphate buffer solution
Working electrode: AuE gold electrode, BDDE boron-doped diamond electrode, CE carbon electrode, COGPE graphite paper electrode pretreated by cold reactive plasma using CO2, CoPc–PGE pyrolytic graphite electrode modified with cobalt phthalocyanine, CrGO–GCE glassy carbon electrode modified by chemically reduced graphene oxide, CuE copper electrode, CuO–CuE copper electrode coated with CuO, EPGE electrochemically treated graphite paper electrode, ErGO–GCE glassy carbon electrode modified by electrochemically reduced graphene oxide, GCE glassy carbon electrode, G–ORSPE graphite organic resistant screen-printed electrode, GPE graphite paper electrode, IrO/RuO–GCE glassy carbon electrode modified by electrodeposited Ir-Ru oxides, ITOE indium-doped tin oxide electrode, MWCNTs–BDDE boron-doped diamond electrode modified by multi-walled carbon nanotubes, MWCNTs–GCE glassy carbon electrode modified by multi-walled carbon nanotubes, MWCNTs/rGO–BDDE boron-doped diamond electrode modified by multi-walled carbon nanotubes and reduced graphene oxide, MWCNTs–SPCE screen-printed carbon electrode modified by multi-walled carbon nanotubes, MWCNTs–SPE screen-printed electrode modified by multi-walled carbon nanotubes, NF–MWCNTs–GCE carbon electrode modified by non-functionalized multi-walled carbon nanotubes, NiPb–FTOE fluorine-doped tin oxide electrode modified by Ni and Pb nanoparticles, NiPt–FTOE fluorine-doped tin oxide electrode modified by Ni and Pt nanoparticles, [(NiTRPyP)-μ-O]–GCE glassy carbon electrode modified by polymer [(NiIITRPyP)-μ-O2]n, NiZn–FTOE fluorine-doped tin oxide electrode modified by Ni and Zn nanoparticles, OGPE graphite paper electrode pretreated by cold reactive plasma using O2, rGO–BDDE boron-doped diamond electrode modified by reduced graphene oxide, rGO/RuOHCF–GCE glassy carbon electrode modified by reduced graphene oxide/ruthenium oxide hexacyanoferrate, SnHCF–BDDE boron-doped diamond electrode modified by drop casting with tin hexacyanoferrate, SPAuE screen-printed gold electrode, SPCE screen-printed carbon electrode, SPGE screen-printed graphite electrode, SSE stainless-steel electrode; ZnO/MWCNTs–GCE glassy carbon electrode modified by multi-walled carbon nanotubes and ZnO nanoparticles
Technique: ASV anodic stripping voltammetry, MPA multiple pulse amperometry, SWV square-wave voltammetry, SWASV square-wave anodic stripping voltammetry
Fig. 7Amperometric responses (n = 3) of solution containing 1 × 10–5 mol dm−3 UA, 1 × 10–5 mol dm−3 NIT, and 1 × 10–5 mol dm−3 mixture solution of UA and NIT. Potential pulses: 0.45 and 0.70 V for 70 ms; supporting electrolyte: BR buffer pH = 2.0; stirring speed of the solution into the BIA cell: 1225 rpm; dispensing rate: 277 mm3 s−1; injection volume: 100 mm3 [87]